Onorateli Myriam, Botana Claudia, Peralta Laura, Rebollo Magali, Ruvinsky Silvina, Guitter Myriam, Felice Maria S, Posadas Mercedes, Evangelista Silvina, Villar Maria V, Golluscio Mariana, Molina Agustina, Fraquelli Lidia
Hospital de Pediatría SAMIC "Prof. Dr. Juan P. Garrahan", Ciudad Autónoma de Buenos Aires, Argentina.
Arch Argent Pediatr. 2016 Dec 1;114(6):549-552. doi: 10.5546/aap.2016.eng.549.
Chemotherapy regimens and clinical support advances have improved survival in children with acute lymphoblastic leukemia. The after-effects of treatment are a reason for concern, including damage to the immune system induced by immunosuppressive therapy which is reflected in the loss of antibody protection provided by prior immunizations. Our goal was to assess the presence of measles, rubella, and tetanus protective antibody titers among patients with acute lymphoblastic leukemia after completing chemotherapy. Sixty-one children with acute lymphoblastic leukemia seen at the Hospital Garrahan were included; patients had finished their chemotherapy at least 6 months earlier and had a complete immunization schedule before diagnosis. The rates of protective antibodies were 46% (CI: 32-59) for measles, 53% (CI 40-67) for tetanus, and 60% (CI 47-63) for rubella. These results strengthen the need to reconsider revaccination in this group of patients.
化疗方案和临床支持的进步提高了急性淋巴细胞白血病患儿的生存率。治疗的后遗症令人担忧，包括免疫抑制疗法对免疫系统造成的损害，这表现为先前接种疫苗所提供的抗体保护作用丧失。我们的目标是评估急性淋巴细胞白血病患者完成化疗后麻疹、风疹和破伤风保护性抗体滴度的情况。纳入了61名在加拉汉医院就诊的急性淋巴细胞白血病患儿；这些患者至少在6个月前完成了化疗，并且在诊断前有完整的免疫接种计划。麻疹保护性抗体的比例为46%（置信区间：32 - 59），破伤风为53%（置信区间40 - 67），风疹为60%（置信区间47 - 63）。这些结果强化了重新考虑对这组患者进行再接种的必要性。
